Market Research Logo

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Summary

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), a


Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
Amgen Inc
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
Hyundai Pharmaceutical Co Ltd
Johnson & Johnson
Merck & Co Inc
Takeda Pharmaceutical Co Ltd
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
AM-1638 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasiglifam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUG-770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYDG-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
Featured News & Press Releases
Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development
Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes
May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society
Aug 22, 2012: Takeda Launches Phase III Clinical Trial In Asia For TAK-875 To Treat Diabetes
Feb 27, 2012: Takeda Announces Publication Of Phase II Data Of TAK-875 In The Lancet, Demonstrates Improved Glycemic Control In Patients With Type 2 Diabetes
Oct 18, 2011: Takeda Initiates Phase III Clinical Trial Program In US, Latin America, And Europe For Investigational Type 2 Diabetes Therapy TAK-875
Sep 12, 2011: Takeda's TAK-875 Enters Into Phase III Clinical Trials For Treatment Of Type 2 Diabetes In Japan
Jun 28, 2011: Takeda Presents Late Breaking Data Of TAK-875 At American Diabetes Association 71st Annual Scientific Sessions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Cadila Healthcare Ltd, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report